Home
/
RELIGION & LIBERTY ONLINE
/
Why cheap drugs from Canada won’t reduce U.S. Drug prices
Why cheap drugs from Canada won’t reduce U.S. Drug prices
Oct 7, 2024 2:21 AM

If you suffer from acid reflux, your doctor may prescribe Nexium. But at $9 a pill, the price is enough to give you a worse case of heartburn.

That’s the lowest price in the U.S. If you live in Canada, though, you can get the drug for less than a $1 a pill.

This price disparity leads many politicians to think the solution is obvious: Americans should just buy drugs from Canada or other countries where they are cheaper.

Its plan supported by economic liberals like President Trump and Bernie Sanders. Several years ago Sen. Amy Klobuchar (D-Minn.) and John McCain (R-Az.) twice introduced legislation to allow Americans to order up to a 90-day supply of medicines from a licensed Canadian pharmacy. The Democratic Party even made it a part of their party platform in 2016.

If this seems too easy, it’s because it’s an economically ignorant idea. Writing in the Harvard Business Review a few years ago, Rafi Mohammed explained why this strategy won’t work:

The reason why pharmaceutical prices are relatively high in the U.S. is panies employ mon strategy called differential pricing. This strategy targets specific segments with different prices. So instead of having the same price for everyone, the goal is to tailor the “right” price to various segments. Movie theaters, for instance, use differential pricing by offering lower prices to students and seniors. The assumption is students and seniors are sensitive to price, sooffering targeted discounts to them is profitable. As a result, moviegoers seated next to each other often have paid different prices.

For differential pricing to be profitable, targeted segments have to be easily identifiable, and,most importantly, arbitrage cannot occur. By arbitrage, I mean those who receive discounts don’t resell to customers who are currently paying more. This strategy works well at cinemas: it’s easy to identify seniors/students, and since tickets are sold individually at the door, enterprising seniors/students typically aren’t reselling discounted tickets for a profit.

Why are drug prices so much higher in the U.S.? The answer is straightforward: most countries regulate prices or have a single-payer health care system, in which the government pays for citizens’ health care costs. In a single-payer system, the government buys all a country’s pharmaceuticals, and it has leverage in “take it or leave it” negotiations with panies.

Mohammed’s explanation is helpful, but it’s also plete. What he doesn’t mention is the reason whythe price differential for drugs can work: because expensive medicines in the U.S. subsidize the creation of drugs for the entire world.

According to the pharmaceutical giant Eli Lilly, the average cost to discover and develop a new drug is between $800 million to $1.2 billion, and the average length of time from discovery to patient is 10 to 15 years.

If a product costs $1 billion to produce and bring to market, that is the initial fixed cost. Think of it this way: the initial cost to produce the very first Nexium pill is roughly $1 billion. But once that first pill is created, the cost to produce the second, third, fourth, . . . hundred thousandth pill is very low. But if the initial fixed cost cannot be recovered, then pany will lay out the money and spend a decade or more creating the product. New medications will simply not exist.

This point should be obvious—and yet it is widely overlooked and ignored. People see a drug, like Nexium, and forget that it only exists because a pany believed it could recoup the cost of research and development and make a profit by selling the medicine. But how is pany able to earn back the initial billion dollar fixed costs? By charging some buyer—whether a government, HMO, pany or individual—a price that will cover the initial fixed costs.

Once that fixed costs of creating the drug is covered, though, the price can be reduced since the remaining variable costs (e.g., the cost to produce each individual pill) tend to be relatively low. And this brings us to why you, as an American, pay a higher price for a drug that Canadians and Europeans get much cheaper.

To make it easier to understand, let’s imagine that a medicine is created to cure a single disease in three patients living in America, Canada, and France. Now let’s say that the patient in America pays all of the fixed cost ($1 billion), plus the variable cost for one pill (50 cents), plus 50 cents in profit for pany. In total, the American ends up paying $1,000,000,001 for a single pill.

The pany is happy because they recouped their costs and made a profit (50 cents). Canada and France say that they too want to buy the drug, but they will pay only $1. The pany agrees to sell the pill for $1 to both Canada and France because an additional $1 profit is better than $0 in additional profit. Everyone is happy.

Well, maybe not everyone. The American may say that it wasn’t fair for them to pay all the fixed costs —and they’d be right. In our example, Canada and France are free riders that are able to take advantage of the lower costs only because the Americans have already paid the exorbitant fixed costs. The American subsidized the cost of the drug for the patients in the other countries.

This is exactly what happens with most drugs. Very few new medicines are produced in countries that have government restrictions on drug prices. And almost no new drugs would be produced if all countries had government restrictions on drug prices. Without the willingness of the United States to pay the higher prices, the drugs would never e into existence. Countries like Canada and France are like roommates who let you pay full price for a pizza but expect you to give them a slice in exchange for a few pennies they found in the couch.

Which brings us back to the “reimport the drugs” strategy. The reason this approach won’t work is because once Americans stop subsidizing the drugs for the rest of the world, panies will not be able to recoup their costs for R&D. paniessimply won’t be able to afford to create innovative new medicines. That makes everyone worse off than before.

Ultimately, socialized medicine—in the form of government-imposed drug pricing—doesn’t work for the same reason Margaret Thatcher said socialist governments don’t work: “They always run out of other people’s money.”

Comments
Welcome to mreligion comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
RELIGION & LIBERTY ONLINE
What Can Save Chicago?
Chicago is in serious trouble. There has been a rash of crime over the past few weeks that has brought attention, yet again, to a city that cannot seem to make much progress. The Chicago Tribune reported the following about how out of control the city was this past Father’s Day: At least 34 people were shot — nine of them fatally — Saturday afternoon through Father’s Day Sunday, stretching from 94th Street and Loomis Avenue on the South Side...
Natural Resources are Human Resources
If the PowerBlog has a favorite atheist libertarian economist, it’s probably George Mason professor Don Boudreaux. Although he isn’t a believer, he sometimes stumbles upon what I would consider to be Christian insights. Consider, for instance, his take on the term “natural resources”: In nearly all contexts, words and phrases inevitably convey not only information (such as, as Deirdre would say, “telephone numbers”), but also ideas – notions – interpretations – perspectives – biases – prejudices – spins -approval or...
Video: Bill McGurn’s Keynote Address at Acton University
We’re still working on finishing production on the audio and video captured last week at Acton University 2013. Here’s William McGurn, Editorial Page Editor at the New York Post and former speechwriter for President George W. Bush, addressing Acton U participants last Thursday night: ...
Sex Trafficking, China’s One-Child Policy And Gendercide
As reported here last week, the US State Department has released its 2013 “Trafficking In Persons” or Tip Report. In it, China has been reduced to a Tier 3 ranking, the lowest ranking a nation can receive. That means the nation is doing little or nothing ply with international laws regarding the trafficking of persons. According to the Population Research Institute, the State Department acknowledges that China’s one-child policy (which is directly linked to gendercide) has heavily influenced that nation’s...
Fr. Gregory Jensen: East Meets West: Asceticism and Consumerism
Last Friday at Acton University, Fr. Gregory Jensen gave an engaging lecture on the dual subject of asceticism and consumerism. The “East Meets West” part might not be what many would expect. Rather than contrast a consumerist West with an ascetic East, Fr. Gregory insists that both consumerism and asceticism transcend cultures and traditions. Inasmuch as all people take part in consumption, an ascetic answer to the challenge of consumerism is (or ought to be) where East meets West. The...
How the Quality of Marriages Affects a Country’s Economy
The quality of children and our future society, depends directly on the quality of the marriage of their parents, says Pat Fagan of the Family Research Council speaking at the recent World Congress of Families: Fagan notes that society is made up of five facets: the family, church, school, the marketplace and government. The first three mentioned are the places that “grow the people” so to speak, and are closely interrelated. The last two areas of society are those into...
Fr. Michael Butler: Orthodoxy and Natural Law
Today at Acton University, Fr. Michael Butler gave an engaging lecture on the subject of Orthodoxy and natural law. Despite the contemporary ambivalence among many Orthodox (if not hostility) toward natural law, Fr. Michael argues that it is present in the Eastern Tradition from the ancient to the medieval and modern periods, focusing especially on the thought of the seventh century Byzantine Saint Maximus the Confessor. A few months ago, I observed, While it may be that there are important...
Are Socially Responsible Businesses Bad for Society?
In Foreign Policy, Daniel Altman argues that over the long-term panies are often better for society than so-called socially responsible business initiatives: As Jonathan Berman and I have written in the past, panies that take a long time horizon in their decision-making are likely to make more social and environmental investments. Things like training workers, munities, and protecting ecosystems can take a long time to pay off for panies. When they do, the return — including a stronger labor pool,...
The Rise of the $10 Philanthropist
Laura Arrillaga-Andreessen, a lecturer at Stanford University, on what makes a philanthropist: WSJ: How do you define a philanthropist? Ms. Arrillaga-Andreessen: A philanthropist is anyone who gives time, money, experience, skills, networks [or] passion. The only thing that you need is generosity. For example, [recently] after class I counseled a puter science student who wanted to talk about how he could play a role in changing how engineering is taught globally. So we started developing a strategy for how he...
U.S. State Department Releases 2013 Human Trafficking Report
The U.S. State Department has released its annual “Trafficking in Persons” (Tip) report, used to not only further educate people about global human trafficking, but to identify countries where trafficking is most problematic. The report gives each nation a “tiered” rating. Tier 1 countries are those that ply with international laws and standards of the the Trafficking Victims Protection Act. Tier 2 nations are on a watch list as they are making efforts ply with the Act, but are still...
Related Classification
Copyright 2023-2024 - www.mreligion.com All Rights Reserved